Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGCAT study
jRCTs051190024Completed
- Sponsor
- Not applicable
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of edoxaban in cancer-associated thrombosis (CAT), ovarian cancer and endometrial cancer (EC), sponsored by Not applicable. Primary endpoint: Variations in edoxaban plasma concentration before and after chemotherapy (rate difference). Started Apr 2019; status: completed.
02
Drugs
edoxaban
03
Conditions
cancer-associated thrombosis (CAT)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on jRCTs051190024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190024.